You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

CLINICAL TRIALS PROFILE FOR NUVARING


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Nuvaring

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00269620 ↗ PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra Completed Magee-Womens Hospital Phase 4 2005-06-01 This is an open-label prospective, multicenter, randomized trial to compare continuation rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred women will be recruited at 9 centers nationwide to be randomly assigned to use either the NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently stopped the pill and be relatively satisfied with oral contraceptive use to qualify for enrollment. Two visits and two phone calls will be required.
NCT00269620 ↗ PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra Completed Organon Phase 4 2005-06-01 This is an open-label prospective, multicenter, randomized trial to compare continuation rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred women will be recruited at 9 centers nationwide to be randomly assigned to use either the NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently stopped the pill and be relatively satisfied with oral contraceptive use to qualify for enrollment. Two visits and two phone calls will be required.
NCT00269620 ↗ PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra Completed University of Pittsburgh Phase 4 2005-06-01 This is an open-label prospective, multicenter, randomized trial to compare continuation rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred women will be recruited at 9 centers nationwide to be randomly assigned to use either the NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently stopped the pill and be relatively satisfied with oral contraceptive use to qualify for enrollment. Two visits and two phone calls will be required.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nuvaring

Condition Name

Condition Name for Nuvaring
Intervention Trials
Contraception 6
Infertility 2
HIV 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nuvaring
Intervention Trials
Vaginosis, Bacterial 3
Infertility 2
Polycystic Ovary Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nuvaring

Trials by Country

Trials by Country for Nuvaring
Location Trials
United States 28
Kenya 2
Thailand 2
Canada 2
Peru 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nuvaring
Location Trials
Virginia 3
New York 3
Illinois 3
California 3
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nuvaring

Clinical Trial Phase

Clinical Trial Phase for Nuvaring
Clinical Trial Phase Trials
Phase 4 11
Phase 3 2
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nuvaring
Clinical Trial Phase Trials
Completed 17
Unknown status 4
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nuvaring

Sponsor Name

Sponsor Name for Nuvaring
Sponsor Trials
Merck Sharp & Dohme Corp. 8
Organon 4
National Institute of Allergy and Infectious Diseases (NIAID) 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nuvaring
Sponsor Trials
Other 26
Industry 17
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

NuvaRing: Clinical Trials, Market Analysis, and Projections

Introduction

NuvaRing, a flexible vaginal ring, is a popular contraceptive method that releases a combination of etonogestrel and ethinyl estradiol to prevent pregnancy. This article delves into the clinical trials, market analysis, and future projections for NuvaRing, providing a comprehensive overview of its acceptability, market trends, and growth prospects.

Clinical Trials and Acceptability

Satisfaction and Continuation Rates

Clinical trials have consistently shown high satisfaction rates among users of NuvaRing. Studies indicate that general satisfaction, measured as being satisfied or very satisfied, ranges between 80% and 90%[1].

  • In various settings, including high-income countries and some regions in Latin America, Asia, and Africa, NuvaRing users reported high satisfaction levels. For instance, a study in Rwanda showed over 80% satisfaction, aligning with qualitative findings and user feedback[1].

Sexual Satisfaction

The impact of NuvaRing on sexual satisfaction is mixed but generally positive. Some studies in Italy reported improvements in all variables related to sexual function and relationship satisfaction compared to baseline and other contraceptive methods[1].

  • A study in Belgium noted increased sexual desire among NuvaRing users compared to users of combined oral contraceptives (COC) or progestin-only pills[1].

Side Effects and Continuation

While NuvaRing is generally well-tolerated, some users experience minor side effects. In a study among adolescents in the US, 5 out of 32 participants discontinued due to ring-related events[1].

  • Continuation rates vary, but NuvaRing often shows higher continuation rates compared to other contraceptive methods like the skin patch. However, it may have lower continuation rates compared to long-acting reversible contraception methods like intrauterine devices (IUDs) and implants[1].

Market Analysis

Market Size and Growth

The vaginal ring market, dominated by NuvaRing, is valued at USD 2,116.54 million in 2021 and is projected to reach USD 3,450.43 million by 2030, growing at a compound annual growth rate (CAGR) of 5.58%[2].

Key Drivers

Several factors drive the growth of the vaginal ring market:

  • Increasing Disposable Income: Higher disposable incomes, particularly in Pacific Rim countries like Malaysia, Indonesia, and Vietnam, are expected to fuel market growth[2].
  • Rising Awareness and Acceptance: Progressive attitudes towards contraception and the increasing number of working women contribute significantly to market growth[2].
  • Affordable Access: The approval and launch of generic versions, such as EluRyng by Amneal Pharmaceuticals, enhance affordable access to these products, further driving market expansion[3][4].

Market Segmentation

The global vaginal ring market is segmented by type, application, and geography:

  • By Type: NuvaRing is a dominant product, with other types including Estring and Femring[2].
  • By Application: The market is segmented into hospital, clinic, retail pharmacies, and online pharmacies[2].
  • By Geography: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are key regions, with North America and Europe being significant markets[2].

Competitive Landscape

Key Players

The market is competitive, with several key players:

  • Bayer AG: The original manufacturer of NuvaRing.
  • Amneal Pharmaceuticals: Approved the first generic version of NuvaRing, EluRyng, which has been commercially launched[3][4].
  • Other Manufacturers: Companies like The Female Health Company also play a role in the market[2].

Porter’s Five Forces

The competitive landscape can be analyzed using Porter’s Five Forces framework, which helps in understanding the behavior of competitors and assessing the attractiveness of the sector. This includes the threat of new entrants, the bargaining power of suppliers and buyers, the threat of substitute products, and the intensity of rivalry among existing competitors[2].

Projections and Future Outlook

Market Growth Projections

The vaginal ring market is expected to continue growing, driven by increasing awareness and acceptance of contraceptive methods, especially in emerging economies. The CAGR of 5.58% from 2023 to 2030 indicates a steady and significant growth trajectory[2].

Impact of Generic Versions

The introduction of generic versions like EluRyng is expected to increase market competition and reduce costs, making these products more accessible to a broader population. This could lead to higher adoption rates and further market expansion[3][4].

Global Health Initiatives

Proactive initiatives by governments for population control and family planning are also anticipated to drive the growth of the contraceptive devices market, including vaginal rings. Rising awareness among the general population in emerging countries will play a crucial role in this growth[5].

Key Takeaways

  • High Satisfaction Rates: NuvaRing users generally report high satisfaction rates, with many studies showing between 80% and 90% satisfaction.
  • Mixed Sexual Satisfaction: While some studies show improved sexual satisfaction, results are mixed and can vary by population and setting.
  • Market Growth: The vaginal ring market is projected to grow at a CAGR of 5.58% from 2023 to 2030, reaching USD 3,450.43 million by 2030.
  • Generic Versions: The approval and launch of generic versions like EluRyng are expected to enhance affordability and accessibility.
  • Global Health Initiatives: Government initiatives for population control and rising awareness in emerging countries will drive market growth.

FAQs

What is NuvaRing and how does it work?

NuvaRing is a flexible vaginal ring that releases etonogestrel and ethinyl estradiol to prevent pregnancy. It is inserted into the vagina for 3 weeks, removed for 1 week, and then a new ring is inserted.

What are the satisfaction rates for NuvaRing users?

Satisfaction rates for NuvaRing users are generally high, ranging between 80% and 90% in various studies.

What are the common side effects of NuvaRing?

Common side effects include minor ring-related events, concerns about efficacy, negative effects on sexual desire, future fertility issues, and non-suppression of menstruation.

Is there a generic version of NuvaRing available?

Yes, Amneal Pharmaceuticals has received FDA approval for EluRyng, the first generic version of NuvaRing.

What is the projected market size for vaginal rings by 2030?

The vaginal ring market is projected to reach USD 3,450.43 million by 2030, growing at a CAGR of 5.58% from 2023 to 2030.

Sources

  1. Frontiers in Global Women's Health: "Acceptability and Satisfaction of Contraceptive Vaginal Rings in Different Settings: A Systematic Review"
  2. Verified Market Research: "Vaginal Ring Market Size, Share, Trends, Growth & Forecast"
  3. Amneal Pharmaceuticals: "Amneal Receives Abbreviated New Drug Application Approval for EluRyng, the First Generic NuvaRing"
  4. Pharmacy Times: "FDA Approves First Generic Version of NuvaRing"
  5. Fortune Business Insights: "Contraceptive Devices Market Size, Share | Report [2032]"

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.